Journal article
Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)
Abstract
BackgroundA randomised study to assess the addition of apatorsen, an antisense oligonucleotide that inhibits Hsp27 expression, to docetaxel in patients with metastatic urothelial carcinoma (mUC) relapsed after prior platinum-based chemotherapy.MethodsMulticentre, phase II study with 1:1 randomisation to apatorsen (three loading doses at 600 mg intravenous followed by weekly doses) plus docetaxel (75 mg/m2 intravenous every 21 days) (A/D) or …
Authors
Rosenberg JE; Hahn NM; Regan MM; Werner L; Alva A; George S; Picus J; Alter R; Balar A; Hoffman-Censits J
Journal
British Journal of Cancer, Vol. 118, No. 11, pp. 1434–1441
Publisher
Springer Nature
Publication Date
May 2018
DOI
10.1038/s41416-018-0087-9
ISSN
0007-0920
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Administration, IntravenousAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellDocetaxelDown-RegulationDrug Administration ScheduleFemaleGene Expression Regulation, NeoplasticHSP27 Heat-Shock ProteinsHeat-Shock ProteinsHumansMaleMiddle AgedMolecular ChaperonesOligonucleotidesRecurrenceSurvival AnalysisTreatment OutcomeUrologic Neoplasms